EGFR and lung carcinoma: In a phase III clinical trial analyzing recurrent EGFR mutant lung cancer, specificity and sensitivity of molecular ctDNA testing using NGS for detection EGFR sensitizing alterations were 99% (for L858R) and 99% (for exon 19 deletion), respectively, and 62% (for L858R) and 81% (for exon 19 deletion), respecitvely15.